Fulcrum Therapeutics, Inc.
FULCNasdaq
$3.65
↑ +4.3%Jul 17 close · end-of-day
Price
1Y↓ -53.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$278.2M
Enterprise Value
$227.9M
P/E
—
P/S
—
P/B
0.8
EV/EBITDA
—
PEG
—
FCF Yield
-23.0%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$76.1M
Free Cash Flow (TTM)
-$63.9M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-22.8%
ROIC
-24.2%
Debt / Equity
—
Net Cash
$50.3M
Return 1Y
-54.0%
Company profile
Fulcrum Therapeutics, Inc. focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin.
- CEO
- Bryan E. Stuart
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 100
- Headquarters
- Massachusetts
- Website
- fulcrumtx.com
Earnings
FULC Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.25↓ -10.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $8.8M | $19.2M | $6.3M | $2.8M | $80.0M | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$71.6M | -$81.1M | -$112.6M | -$110.7M | -$21.9M | -$84.8M |
| Net income | -$70.8M | -$80.8M | -$109.9M | -$97.3M | -$9.7M | -$74.9M |
| Diluted EPS | -$2.79 | -$2.29 | -$2.44 | -$1.59 | -$0.16 | -$1.18 |
| Operating cash flow | -$53.7M | -$78.5M | -$97.0M | -$91.0M | -$2.2M | -$60.1M |
| Free cash flow | -$55.0M | -$80.2M | -$99.0M | -$91.5M | -$2.5M | -$60.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -811.6% | -423.0% | -1774.9% | -3945.2% | -27.4% | — |
| Net margin | -802.7% | -421.9% | -1732.4% | -3470.2% | -12.2% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $80.0M | $0.00 | $0.00 | — | $0.00 | $0.00 | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $52.5M | -$25.1M | -$19.4M | -$20.4M | -$19.8M | -$21.9M | -$22.7M | -$22.2M |
| Net income | $55.4M | -$21.7M | -$16.6M | -$17.7M | -$17.3M | -$19.6M | -$20.3M | -$18.9M |
| Diluted EPS | $0.87 | -$0.35 | -$0.25 | -$0.28 | -$0.28 | -$0.31 | -$0.31 | -$0.25 |
| Operating cash flow | $58.9M | -$19.1M | -$16.8M | -$15.3M | -$13.8M | -$14.2M | -$16.8M | -$18.8M |
| Free cash flow | $58.9M | -$19.1M | -$17.0M | -$15.3M | -$13.9M | -$14.3M | -$17.0M | -$18.8M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 65.6% | — | — | — | — | — | — | — |
| Net margin | 69.3% | — | — | — | — | — | — | — |
Company news
Jun 27, 2026
Jun 5, 2026
Jun 3, 2026
Jun 2, 2026
- 48d agoThis Biotech Stock Plunges 54%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’finance.yahoo.com
- 48d agoMeta Platforms upgraded, Okta downgraded: Wall Street's top analyst callsfinance.yahoo.com
- 48d agoFulcrum exploring a potential sale after FDA sidelined its sickle cell drugbiopharmadive.com
Jun 1, 2026
- 48d agoFULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Riskstocktwits.com
- 49d agoFulcrum Therapeutics Discontinues Sickle Cell Disease Program After US FDA Raises Malignancy Concernsfinance.yahoo.com
- 49d agoFulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Reviewfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | TANG KEVIN C | Buy | 107,377 | $3.56 | $382,262.12 | filing |
| 2026-07-14 | TANG KEVIN C | Buy | 75,952 | $3.58 | $271,908.16 | filing |
| 2026-07-14 | TANG KEVIN C | Buy | 53,651 | $3.56 | $190,997.56 | filing |
| 2026-07-13 | TANG KEVIN C | Buy | 12,966 | $3.54 | $45,899.64 | filing |
| 2026-06-26 | Ezekowitz Alan | Sale | 18,000 | $3.65 | $65,613.60 | filing |
| 2026-02-02 | Gould Robert J | Sale | 15,000 | $10.72 | $160,857.00 | filing |
| 2026-01-02 | Gould Robert J | Sale | 15,000 | $11.87 | $178,089.00 | filing |
| 2026-01-02 | Gould Robert J | Sale | 15,000 | $10.87 | $163,089.00 | filing |
| 2025-12-15 | Oltmans Curtis Gale· Chief Legal Officer | Sale | 3,452 | $12.92 | $44,599.84 | filing |
| 2025-12-08 | RA CAPITAL MANAGEMENT, LLC | Sale | 2,706,397 | $14.28 | $38.6M | filing |
| 2025-12-08 | RA CAPITAL MANAGEMENT, LLC | Sale | 1,377,020 | $13.33 | $18.4M | filing |
| 2025-12-08 | RA CAPITAL MANAGEMENT, LLC | Sale | 91,722 | $14.98 | $1.4M | filing |
| 2025-11-19 | Gould Robert J | Sale | 15,000 | $11.03 | $165,495.00 | filing |
Latest 13 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.